Introduction
Cardiac metabolic remodelling is proposed to be an important contributor to the development of heart failure. 1 It is generally accepted that the transition process towards heart failure is accompanied by a shift in cardiac substrate preference, with a greater reliance on glucose utilization and a concomitant suppression of fatty acid oxidation (FAO). [2] [3] [4] [5] This metabolic shift seems to precede the onset of cardiac dysfunction. 6 In addition, the failing heart is characterized by an imbalance between energy supply and demand leading to a cardiac energy deficit, i.e. a lower phosphocreatine-to-ATP ratio (PCr/ATP). 7 The myocardial PCr/ATP ratio has been identified as a strong predictor of mortality in heart failure patients. 8 It is currently not clear, however, whether the metabolic shift towards increased glucose utilization upon heart failure is a beneficial adaptive mechanism, and whether it is a cause or consequence of the reduced cardiac energetic status. Type 2 diabetes patients have a 2.5 times higher risk of heart failure compared with subjects without diabetes. 9 The diabetic heart almost exclusively (90-100%) relies on FAO and has lost the flexibility to switch from FAO to glucose utilization. 10 Moreover, the diabetic heart has a decreased energy status 11 and an impaired function. 12 Hence, the virtually complete reliance on FAO is potentially detrimental for the diabetic heart, and a possible shift from FAO towards glucose utilization upon heart failure may thus be a beneficial adaptation. In the non-diabetic condition, there are indeed indications that increased glucose utilization could be favourable, [13] [14] [15] although it has also been reported that increased FA utilization is beneficial 3, 16, 17 and that reduced FAO can lead to exacerbated cardiac dysfunction [18] [19] [20] [21] (reviewed in   22 ). However, as the metabolic phenotype of the diabetic heart differs from that of the normal heart, it remains to be elucidated whether high FA utilization in the diabetic heart is beneficial in assisting the diabetic heart to cope with conditions promoting heart failure. Of note, this could shed light on the 'obesity paradox', i.e. the phenomenon that the prognosis for obese heart failure patient is better than that for non-obese heart failure patients. 23 To investigate how changes in cardiac substrate preference predict the development of heart failure, an in vivo longitudinal study setting is crucial to allow studying the time course of changes in cardiac metabolism and energetics in relation to the decline in cardiac function. After all, evidence for a link between heart failure and changes in cardiac metabolism largely originates from ex vivo studies using isolated perfused hearts, and such studies cannot fully mimic the in vivo condition. The diabetic heart, for example, is exposed to a hyperglycemic, hyperlipidemic, and hyperinsulinemic environment, which will affect the choice of substrates. 10 Furthermore, the type and concentration of substrates may change during the development of heart failure, which is difficult to address in ex vivo studies.
Here, we aim to quantify the cardiac metabolic, structural, and functional changes during heart failure progression in non-diabetic and diabetic mice in vivo in a longitudinal study design and investigate how the metabolic profile of the diabetic heart is related to the cardiac metabolic and structural remodelling upon pressure overload (as a model of nonischemic cardiomyopathy). Pressure overload was induced by transverse aortic constriction (TAC) surgery. Non-invasive magnetic resonance imaging (MRI), 31 P magnetic resonance spectroscopy (MRS), 1 H MRS, and 18 F-fluorodeoxyglucose positron emission tomography ( 18 F-FDG-PET) were applied to measure cardiac function, energy status, lipid content, and glucose uptake, respectively, at baseline and 1, 5, and 12 weeks post-TAC. The in vivo data were complemented with measurements of ex vivo mitochondrial oxidative capacity and expression levels of proteins involved in mitochondrial oxidative phosphorylation, tricarbocylic acid cycle, fatty acid b-oxidation, and hypertrophic signalling pathways. Our results show that heart failure development in non-diabetic mice correlated with increased protein kinase D-1 (PKD1) phosphorylation and increased myocardial FDG uptake, which preceded the decrease in cardiac energy status. Furthermore, we show that the cardiac metabolic adaptations and signalling in diabetic mice seem to prevent the heart from failing upon pressure overload.
Methods

Animals
Male non-diabetic (db/þ) and diabetic (db/db) C57BL/Ks mice (10 weeks of age) were purchased from Charles River. The animals were housed in a specific pathogen-free animal facility of Eindhoven University of Technology in individually ventilated cages and in the conventional facility of Münster University, under controlled temperature (23 C) and hu- H MRS, and PET measurements in Münster, Germany; (iii) for baseline ex vivo high-resolution respirometry, proteomics, and western blot analyses. Animals (sets 1 and 2) underwent TAC surgery (needle size: 27 G) to induce pressure overload, as described previously. 24 To follow the progression of cardiac hypertrophy and failure, the PET and/or MR measurements were performed before, 1, 5, and 12 weeks post-TAC. The surgery and the measurements were performed under isoflurane anaesthesia (induction: 3-4%, maintenance: 2-3% for surgery; 1-2% for measurements, in 0.2 l/min medical air and 0.2 l/min O 2 ). Analgesic buprenorphine (0.1 mg/kg) was administered subcutaneously 12 h before the surgery and repeated daily for 3 days. The animals were sacrificed by cervical dislocation under isoflurane anaesthesia, after the measurements at 12 weeks post-TAC (sets 1 and 2) or at baseline (set 3). The heart was excised and half of it was used immediately for isolation of mitochondria for high resolution respirometry and proteomics measurements. The other part was frozen in liquid nitrogen for western blotting. All procedures conformed to the Directive 2010/63/EU of the European Parliament, and were approved by the Animal Experimental Committees of Maastricht University (The Netherlands) and The North Rhine-Westphalia Agency for Nature, Environment, and Consumer Protection (Landesamt für Natur, Umwelt und Verbraucherschutz Nordrhein-Westfalen-LANUV, Germany).
MRI and MRS
Cardiac-triggered and respiratory-gated cine MRI, 1 H MRS, and 31 P MRS were performed to measure cardiac function, lipid content, and energy status, respectively. Additionally, to determine the severity of the TAC surgery, blood flow through right and left carotid arteries was measured using a flow velocity encoded MRI sequence. Details of the MRI/MRS and all other experimental methods are provided in the Supplementary material online.
Positron emission tomography
PET measurements were performed after a 12-13 h overnight fast. The acquisition was performed 1 h after 18 F-FDG injection ($10 MBq in 100 ll), for 15 min.
Pressure overload in diabetic mice
Fasting plasma glucose
Plasma glucose levels were measured after a 4 h fast in one drop of blood using a Glucose-201 glucose meter (HemoCue, € Angelholm, Sweden).
High-resolution respirometry
A two-channel high-resolution Oxygraph-2k (Oroboros, Innsbruck, Austria) was used to measure oxygen consumption rates in isolated cardiac mitochondria using (i) pyruvate plus malate or (ii) palmitoyl-CoA plus L-carnitine plus malate as substrates.
Targeted quantitative mitochondrial proteomics
Fifty-four mitochondrial proteins involved in substrate transport, FAO, and the TCA cycle were quantified in isolated mitochondria using isotopically labelled standards ( 13 C-labelled lysines and arginines). 
Western blot analyses
RNA expression analyses
RNA expression analyses were performed in cardiac muscle homogenates to determine the expression of atrial natriuretic factor (ANF) and brain natriuretic peptide (BNP). The quantitative polymerase chain reaction (PCR) values were corrected to Cyclophilin A expression levels and normalized with respect to baseline controls.
Statistics
Data are presented as means ± SD. Statistical significance of genotype (non-diabetic and diabetic mice) and time (baseline, 1, 5, and 12 weeks post-TAC) effects were assessed by applying a two-way analysis of variance in the IBM SPSS 21.0 (SPSS Inc., Chicago, IL, USA). The general genotype effects and the general time effects were reported only when the interaction term between genotype and time was not significant. In case of a significant general effect of time, Fisher's least significant difference (LSD) post-hoc tests were performed to identify differences between different time points. In case the interaction term between genotype and time was significant, the simple main effects between genotypes at each time point and within the same genotype between different time points were evaluated using Estimated Marginal Means (EMMEANS). Correlations between parameters were assessed using a Pearson's correlation. Statistical significance was set at P < 0.05.
Results
Animal characteristics
Physiological characteristics of the mice are shown in Table S1 , see Supplementary material online. Body weight of the diabetic mice was 1.5-1.8 times higher than that of non-diabetic mice at all time points (P < 0.001). Plasma glucose levels were three to five times higher in diabetic than in non-diabetic mice at all time points (P < 0.05). At 12 weeks post-TAC, wet lung weights were lower in diabetic than in non-diabetic mice (P = 0.016). In non-diabetic mice, wet lung weights were higher at 12 weeks post-TAC compared with baseline (P = 0.041, respectively), indicating pulmonary congestion.
Post-surgical mortality
A total of 36 diabetic mice and 26 non-diabetic mice were involved in the study. The TAC surgical procedure appeared to be less tolerated by the diabetic mice; 18 diabetic mice compared with 3 non-diabetic mice died within a few hours up to 2 days after surgery. After this critical time, the mortality rate was 33% and 14% at 12 weeks post-TAC for non-diabetic and diabetic mice, respectively (data from Set 1 animals). Mortality rates in Set 2 animals were higher compared with Set 1 animals, especially for diabetic mice, which is likely related to the more intensive experimental protocol involving overnight fasting prior to PET measurements, followed by two sessions of anaesthesia within a 3-day period.
TAC affected left ventricular mass and function severely in non-diabetic mice, but only mildly in diabetic mice
Blood flow velocities in right and left carotid arteries indicate the degree of constriction of the aortic arch by the TAC procedure. At 1 week after TAC, blood flow was similarly increased in the right and decreased in the left carotid arteries in non-diabetic and diabetic mice (see Supplementary material online, Figure S1 ), indicating that the pressure overload achieved after surgery was comparable between genotypes. Furthermore, blood flow velocities in the carotids remained similar between non-diabetic and diabetic mice at 5 weeks post-TAC (see Supplementary material online, Figure S1 ; data at 12 weeks post-TAC not available), indicating no differences in band integrity between groups. In non-diabetic mice, left ventricular (LV) mass ( Figure 1A , B) progressively increased from a 37% increase with respect to baseline at 1 week post-TAC (P < 0.001 vs. baseline) to a 92% increase at 12 weeks post-TAC (P < 0.001 vs. baseline). Interestingly, the increase in LV mass was less pronounced in diabetic mice, in which LV mass only increased by 20% at 1-week post-TAC (P = 0.038 vs. baseline) and by 52% at 12 weeks post-TAC (P < 0.001 vs. baseline). At 12 weeks post-TAC, LV mass was 28% lower in diabetic as compared with non-diabetic mice (P < 0.001).
In non-diabetic mice, the progressive hypertrophy upon TAC was accompanied by increases in end-diastolic and end-systolic volumes (ESV) over time ( Figure 1C, D) , resulting in a 30% reduction in stroke volume (SV) at 1 week post-TAC (P < 0.001 vs. baseline), which was maintained until 12 weeks post-TAC ( Figure 1E) . Similarly, in non-diabetic mice, ejection fraction (EF) progressively decreased after TAC, from a 36% decrease with respect to baseline at 1 week post-TAC (P < 0.001 vs. baseline) to a 47% decrease at 12 weeks post-TAC (P < 0.001 vs. baseline).
In contrast, in diabetic mice, ESV and SV were not affected by TAC ( Figure 1D , E). Moreover, in diabetic mice, EF was preserved at 1 and 12 weeks post-TAC (P = 0.101 and 0.157 vs. baseline, respectively), while it was slightly decreased at 5 weeks post-TAC (16%, P = 0.030 vs. baseline).
Peak filling rate, a measure of cardiac diastolic function, was significantly higher in diabetic mice compared with non-diabetic mice at 5 weeks post-TAC (P = 0.001; Figure 1G 
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Myocardial FDG uptake was lower in diabetic mice, but increased in both nondiabetic and diabetic mice upon TAC Myocardial glucose uptake was measured in vivo in the LV using 18 F-FDG-PET (Figure 2A) . At baseline, FDG uptake was 44% lower in diabetic mice than in non-diabetic mice (P = 0.006). In non-diabetic mice, FDG uptake increased 2.2-fold at 1 week post-TAC (P < 0.001 vs. baseline) and remained increased at 5 weeks post-TAC (2.5-fold; P < 0.001 vs. baseline; Figure 2B) . Interestingly, the increased myocardial FDG uptake in the non-diabetic mice strongly correlated with changes in 
LV mass and EF (r = 0.834 and r = -0.857, respectively; P < 0.001; Figure 2C , D). Furthermore, the myocardial FDG uptake in the nondiabetic mice also correlated with SV (r = -0.526, P = 0.001) and CO (r = -0.565, P = 0.001). In diabetic mice, FDG uptake increased at 1 week post-TAC compared with baseline (2.4-fold; P = 0.011; Figure 2B ). After TAC, FDG uptake in diabetic mice remained lower than in non-diabetic mice, but reached a level that was similar to the baseline level of nondiabetic mice. Similar results were obtained when FDG uptake was normalized to LV mass (see Supplementary material online, Figure S2 ).
In vivo myocardial lipid content was higher in diabetic mice but not affected by TAC
Myocardial lipid content was measured in the myocardial septum using 1 H MRS ( Figure 3A) , by quantifying the triglyceride (TG) methylene peak relative to the water signal ( Figure 3B) . Myocardial TG levels were $50% higher in diabetic mice compared with non-diabetic mice (general genotype effect P < 0.001), but were not affected by TAC in either genotype ( Figure 3C) . Similarly, three other signals associated with TG (TG olefinic, b-methylene, and methyl peaks) were significantly higher in diabetic mice compared with non-diabetic mice (general genotype effects P = 0.003, P = 0.001, and P = 0.052, respectively; data not shown). 3.6 Cardiac energy status decreased in non-diabetic mice upon TAC, while low baseline cardiac energy status in diabetic mice recovered after TAC 31 P MRS of the LV ( Figure 4A ) was used to quantify the myocardial PCr/ ATP ratio as a measure of cardiac energy status in vivo ( Figure 4B, C) . At baseline, the PCr/ATP ratio was 41% lower in diabetic mice than in non- 
diabetic mice (P < 0.001; Figure 4D ). TAC did not affect the PCr/ATP ratio at 1 and 5 weeks post-TAC, but at 12 weeks post-TAC the PCr/ATP ratio was significantly reduced in non-diabetic mice (P = 0.022 vs. baseline) while it was increased in diabetic mice (P = 0.019 vs. baseline; Figure 4D ). In line with the lower cardiac energy status in diabetic mice, total creatine levels as measured by 1 H MRS were lower in diabetic mice compared with non-diabetic mice (general genotype effect P = 0.038; Figure 3D ).
TAC decreased cardiac mitochondrial oxidative capacity, but FAO capacity was better maintained in diabetic mice
We measured mitochondrial oxidative capacity in isolated heart mitochondria of non-diabetic and diabetic mice at baseline and at 12 weeks post-TAC. At baseline, mitochondrial respiratory capacity for a glucosederived substrate (i.e. pyruvate plus malate) was similar between nondiabetic and diabetic mice ( Figure 5A, B) . However, when using a FA substrate to fuel mitochondrial respiration (i.e. palmitoyl-CoA plus carnitine plus malate) state 3 and uncoupled respiratory capacity each were higher in diabetic mice than in non-diabetic mice (general genotype effect P < 0.001 for state 3, P = 0.025 for uncoupled state; Figure 5D , E). At 12 weeks post-TAC, there was a genotype-independent decrease in state 3 and uncoupled respiratory capacity on the glucose-derived substrate compared with baseline (general time effect of $25%; P = 0.001 for state 3, P = 0.013 for uncoupled state; Figure 5A , B). TAC similarly resulted in a genotype-independent decrease in state 3 respiratory capacity on the FA substrate (general time effect P = 0.001; Figure 5D ), but respiration remained higher in diabetic mice than in non-diabetic mice (general genotype effect P < 0.001; Figure 5D ). Interestingly, while uncoupled respiratory capacity of non-diabetic mice for the FA substrate was 35% lower at 12 weeks post-TAC compared with baseline (P = 0.001), uncoupled respiratory capacity of diabetic mice was not affected by TAC (P = 0.362; Figure 5E ). State 4 respiration was similar between nondiabetic and diabetic mice for both substrates, and unaffected by TAC ( Figure 5C, F) . 3 .8 TAC lowered levels of mitochondrial proteins involved in FAO, TCA cycle and oxidative phosphorylation similarly in nondiabetic and diabetic mice
To investigate which steps in the mitochondrial metabolic pathway account for the decreased state 3 respiration upon TAC, we performed proteomics analysis in isolated heart mitochondria at baseline and at 12 weeks post-TAC ( Figure 6) . We measured the levels of mitochondrial proteins involved in b-oxidation ( Figure 6A Pressure overload in diabetic mice electron transfer flavoprotein alpha and beta subunit (ETFA and ETFB), very long-chain acyl-CoA dehydrogenase (VLCAD), short-chain enoylCoA hydratase (ECHS1), medium and short-chain L-3-hydroxyacylcoenzyme A dehydrogenase (HADH), hydroxyacyl-CoA dehydrogenase/3-ketoacyl-CoA thiolase/enoyl-CoA hydratase (trifunctional protein) beta subunit (HADHB), enoyl-CoA delta isomerase 1 (ECI1)] independent of genotype (general TAC effect P < 0.01 Taken together, from a proteomics perspective, an overall downregulation of all steps of mitochondrial metabolism after TAC appears to contribute to the observed decrease in mitochondrial oxidative capacity in both non-diabetic and diabetic hearts.
TAC normalized the phosphorylation level of acetyl-CoA carboxylase in diabetic mice to the baseline levels of non-diabetic mice
To investigate the mechanism underlying the better maintenance of FAO capacity in the diabetic mice after TAC, we measured p-ACC at baseline and 12 weeks post-TAC. Consistent with the higher mitochondrial capacity of diabetic mice to oxidize FA, the ex vivo western blot analysis ( Figure 7A, B) showed higher p-ACC levels and thus increased inhibition of activity of ACC, an enzyme catalyzing the formation of malonyl-CoA, in diabetic mice as compared with non-diabetic mice (general genotype effect P = 0.009). Total ACC was similar between diabetic and non-diabetic mice, and was not affected by TAC ( Figure 7C ).
Hypertrophic signalling pathways
We also studied signalling pathways known to be involved in hypertrophy: the mTOR, [25] [26] [27] [28] 32 . In this study, 12 weeks of TAC did not affect the phosphorylation degree of mTOR ( Figure 7D ) or ERK ( Figure 7E) , and increased the phosphorylation of CAMKII (general TAC effect: P = 0.011; Figure 7F ). However, no genotype effects were found on any of these proteins. On the other hand, while the phosphorylation of PKD1 also increased upon TAC (general TAC effect: P = 0.022), it was lower in diabetic mice than in non-diabetic mice (general genotype effect: P = 0.018; Figure 7G ). The level of phosphorylated PKD1 in diabetic mice at 12 weeks post-TAC was also similar to the level in non-diabetic mice at baseline. Total PKD1 expression was not changed ( Figure 7H) . PKD1, previously classified as PKC-l, has been suggested to be involved in the development of cardiac hypertrophy through the PKD1-HDAC5-MEF2 signalling pathway 33 or through direct effects on glucose uptake. 34 We therefore further explored PKD's downstream targets, i.e. troponin I Figure S3B ), and tended to be lower in diabetic mice (general genotype effect: P = 0.08). However, HDAC5 phosphorylation was not significantly increased upon TAC (see Supplementary material online, Figure  S3C ) and also no genotype effect was detected on the phosphorylation level of HDAC5.
To further explore possible re-activation of the fetal gene program, we measured mRNA levels of the natriuretic peptides BNP and ANF. Although there was an increase in BNP gene expression upon TAC (general TAC effect: P = 0.01; see Supplementary material online, Figure  S3D ), the diabetic mice had reduced expression of BNP (general genotype effect: P = 0.01). ANF gene expression was not changed upon TAC or upon diabetes (see Supplementary material online, Figure S3E ).
Discussion
Here we present the first comprehensive, longitudinal in vivo investigation of short-and long-term cardiac metabolic, structural, and functional changes in non-diabetic and diabetic mice during a time frame of 12 weeks after the induction of pressure overload. The in vivo measurements were complemented with ex vivo high-resolution respirometry, proteomics, western blotting, and quantitative PCR to elucidate the underlying molecular pathways. We observed that in non-diabetic mice, TAC induced cardiac hypertrophy and dysfunction, which was strongly correlated with increased myocardial glucose uptake. TAC also increased the levels of phosphorylated PKD1. Myocardial glucose uptake was increased already early in the development of heart failure in these mice and preceded a decrease in cardiac energy status. In comparison to non-diabetic mice, diabetic mice showed lower myocardial glucose uptake, lower cardiac energy status, and an increased mitochondrial capacity to oxidize FA at baseline. Unexpectedly, TAC affected cardiac function only mildly in diabetic mice within the 12 week time frame after TAC surgery. Also, the increase in LV mass upon TAC was much less pronounced in diabetic mice than in non-diabetic mice. The mild effect of TAC in diabetic mice was accompanied by a normalization of myocardial glucose uptake and the levels of phosphorylated PKD1 to the values of non-diabetic mice at baseline. In addition, the diabetic mice showed a blunted reduction in ex vivo mitochondrial capacity for FAO and a normalization of cardiac energy status at 12 weeks post-TAC. Our data suggest that in diabetic mice myocardial substrate balance is restored upon pressure overload, and that this in turn protects them from pressure overload induced heart failure.
(Mal-)adaptive cardiac metabolic switch towards increased glucose uptake upon pressure overload
The increase in myocardial glucose uptake during heart failure development as observed in this study is in agreement with previous reports showing that increased glucose utilization occurs early in heart failure (reviewed in 35 ). However, it has not been clear whether the metabolic 
shift towards increased glucose utilization during the development of heart failure is an adaptive, or rather a detrimental mechanism. If the increased myocardial glucose uptake was an adaptive response to the increased workload, the correlation between myocardial glucose uptake and the severity of cardiac dysfunction in our non-diabetic mice indicates that this compensatory mechanism still could not prevent the progression towards heart failure. Indeed, previous studies have shown that the hypertrophied heart seems to be unable to increase glucose utilization to the levels required to maintain function, 2, 4 and further stimulation of glucose utilization is necessary to rescue the heart upon pressure overload. 13 On the other hand, preventing an increase in glucose uptake upon TAC by propranolol was shown to protect the heart from failing, 6 suggesting that the shift towards increased glucose utilization is maladaptive. Increased glucose uptake may not be beneficial when it is not matched with a sufficient increase in glucose oxidation, which could be the case in heart failure because of decreased mitochondrial function. Previous studies have shown reduced mitochondrial oxidative capacity upon heart failure in isolated heart mitochondria and permeabilized cardiac fibres of dogs 36, 37 and patients. 38, 39 It has been shown that the mismatch between glucose uptake and glucose oxidation results in the accumulation of glucose-6-phosphate, which activates mTOR and in turn induces cardiac hypertrophy. 28, 35 Our study shows a downregulation of mitochondrial proteins as well as a reduced ex vivo mitochondrial capacity to oxidize glucose-derived substrates at 12 weeks post-TAC in both nondiabetic and diabetic mice. These data indicate that the increase in glucose uptake may not have been matched by a sufficient capacity for glucose oxidation, in particular in non-diabetic mice.
In diabetic mice, however, the TAC-induced increase in myocardial glucose uptake was much lower than in non-diabetic mice and myocardial glucose uptake was in fact normalized to the baseline values of nondiabetic mice. Together with the observation that the levels of mitochondrial proteins and oxidative capacity for glucose-derived substrates were similar between non-diabetic and diabetic mice upon TAC, this may suggest a better matching between glucose uptake and oxidation in the diabetic hearts upon TAC. This, in turn, can be linked with the less pronounced LV hypertrophy in diabetic mice compared with nondiabetic mice; however, in this study, pressure overload-induced LV hypertrophy was not associated with any significant changes in phosphorylated mTOR, suggesting that other pathways leading to hypertrophy are involved.
Another protein that may be involved in hypertrophic signalling is PKD1. 40 Pressure overload induces endothelin production, 41 which in turn activates protein kinase C (PKC) in tissues including heart, resulting in PKC-induced PKD1 activation and phosphorylation. 42 PKD1 overexpression has been associated with increased phosphorylation of HDAC5, 43 and subsequently, transcription of hypertrophic genes regulated by hypertrophic transcription factor MEF2. 40 In addition, PKD1
phosphorylation has previously been shown to induce GLUT4 translocation to the sarcolemma, and consequently, increase glucose uptake. 30, 31 Increased glucose uptake has also been linked to hypertrophy. 44 In this study, TAC led to increased levels of phosphorylated PKD1 in both nondiabetic and diabetic mice, but the levels were consistently lower in the diabetic mice. These data are in agreement with the increased myocardial glucose uptake and hypertrophy upon TAC in the non-diabetic mice, and the overall lower glucose uptake and attenuated hypertrophy Pressure overload in diabetic mice in the diabetic mice. Interestingly, like our diabetic mice, PKD1 knockout mice also show inhibited hypertrophy and better cardiac function in response to pressure overload. 40 Additionally, decreased PKD1 phosphorylation was shown to be involved in the protection against long-term pressure overload in scaffold protein muscle A-kinase anchoring protein b knockout mice. 45 Lower PKD1 phosphorylation in the diabetic mice could therefore explain the protection against pressure overloadinduced hypertrophy and impairment in function. Yet, this PKD1 involvement does not seem to proceed via the classical PKD1-HDAC5-MEF2 axis, given that HDAC5 phosphorylation was not significantly increased upon TAC and was also not lower in diabetic mice compared with nondiabetic mice. More likely, PKD1 thus affects hypertrophy through its direct effects on glucose uptake, resulting in a return to the fetal gene program. Future research is however required to elucidate the link between PKD1 and pressure overload-induced changes in cardiac metabolism, structure, and function.
High FA metabolism in diabetic mice
The diabetic heart primarily relies on FA utilization for energy production. 46, 47 The higher ACC phosphorylation in the diabetic hearts as compared with non-diabetic hearts in this study suggests decreased malonylCoA formation and therefore less inhibition of CPT1b and higher mitochondrial FA uptake in the diabetic hearts. The protein levels of VLCAD, an enzyme involved in FA b-oxidation, were also increased in cardiac mitochondria of diabetic mice, indicating increased FAO. Additionally, the higher myocardial lipid content, higher ex vivo mitochondrial oxidative capacity for FA-derived substrates, and lower myocardial glucose uptake support that the diabetic mice rely more on FA as a substrate for oxidation than on glucose. Although TAC suppressed ex vivo mitochondrial oxidative capacity for FA-derived substrates in non-diabetic mice, the mitochondrial oxidative capacity for FA-derived substrates (in the uncoupled state) was maintained in diabetic mice. Therefore, we speculate that, although TAC led to decreased expression of mitochondrial proteins involved in oxidative metabolism in both non-diabetic and diabetic mice, the maintained mitochondrial capacity to oxidize FA in the diabetic mice may be sufficient to preserve cardiac function upon pressure overload, which is in agreement with a previous study in diabetic and high-fat diet fed mice. 48 This hypothesis is further corroborated by the observation that other mouse models with increased FAO, such as cardiac specific ACC2 knockout mice, 3 were also protected from heart failure upon TAC 3 and Angiotensin-induced pressure overload. 49 Furthermore, it was shown that reducing myocardial FA utilization through ablation of FAT/CD36 or CPT1b, proteins involved in FA transport over the cellular and mitochondrial membranes, respectively, resulted in exacerbated cardiac dysfunction and energetic impairment after TAC.
18,19
Restoration of substrate balance upon pressure overload in diabetic mice
Although the increased reliance on FA metabolism in diabetic mice has actually been linked with detrimental effects related to diabetic cardiomyopathy (reviewed in 50 ), our data suggest that pressure overload restored the myocardial substrate balance 51 in diabetic mice. Twelve weeks of TAC increased myocardial glucose uptake and PKD1 phosphorylation in diabetic mice to the baseline levels of non-diabetic mice.
The restoration of the substrate balance in the diabetic heart could therefore explain why cardiac function was largely maintained in diabetic mice. Interestingly, cardiac energy status in diabetic mice even increased at 12 weeks post-TAC as compared with baseline and 1 week post-TAC. In the non-diabetic mice, the increase in glucose uptake and suppression of FAO upon TAC disturbed the substrate balance and shifted it towards increased dependence on glucose utilization. The importance of maintaining the substrate balance has previously been demonstrated in mice with cardiac-specific PKD1 overexpression. 30 PKD1 overexpressing mice show a shift towards increased glucose utilization, which is paralleled by cardiac hypertrophy and ventricular dilatation. 30 However, feeding PKD1 overexpressing mice a high fat diet normalized cardiac morphology and function. 30 Our observation that diabetic mice were protected against pressure overload, while surprising, is in line with the concept of the 'obesity paradox' in obese heart failure patients. Despite the increased risk of heart failure in obese patients, the prognosis for obese heart failure patients is actually better than that for non-obese heart failure patients. 23 We propose that the restoration of substrate balance could explain this phenomenon.
Reduced cardiac energy status as an effect of heart failure progression
A reduced PCr/ATP ratio in the failing heart has been reported in both animals 52, 53 and patients, 8, 54 and cardiac energy status was shown to be a strong predictor of mortality in heart failure patients. 8 Our data show, however, that the decreased cardiac function in non-diabetic mice, which was already present at 1 week post-TAC, is unlikely to be explained by an impairment of cardiac energetics, as we observed a reduction in the PCr/ATP ratio only at 12 weeks after TAC. Therefore, reduced cardiac energy status rather seems to be an effect of heart failure progression, and may only become prominent when total mitochondrial oxidative metabolism has declined. Furthermore, from the observation that cardiac function of diabetic mice was normal at baseline and was maintained upon TAC despite their low cardiac energy status, which was not recovered until 12 weeks post-TAC, we can conclude that low cardiac energy status does not play a decisive role in the development of heart failure in mice. We suggest that the lack of functional consequences of the low cardiac PCr/ATP ratio in diabetic mice may be explained by a compensatory increase in the forward creatine kinase reaction rate to maintain ATP supply, as shown in a previous study in Zucker diabetic rats. 55 
Limitation of the study
A limitation of this study is the lack of leptin signalling in the db/db mouse model due to leptin receptor deficiency. Obesity is associated with hyperleptinemia. In obese subjects, high levels of circulating leptin have been correlated with cardiac hypertrophy, but animal studies have not supported a role for leptin in promoting cardiac hypertrophy. 56 As the role of leptin in cardiac remodelling remains unclear, one has to consider the lack of leptin signalling in db/db mice when translating our finding to other, non-genetic models of diabetes or to the human situation.
Concluding remarks
Taken together, this study provides the first longitudinal in vivo data of cardiac metabolic, energetic, structural, and functional adaptations during heart failure development and progression in non-diabetic and diabetic mice. Our data show that the development of heart failure in nondiabetic mice was correlated with increased PKD1 phosphorylation and increased myocardial glucose uptake, which preceded the decrease in cardiac energy status. Although diabetic mice showed lower PKD1
